OncoMatch/Clinical Trials/NCT06850623

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

Is NCT06850623 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Acoustic Cluster Therapy and Modified FOLFIRINOX for locally advanced pancreatic adenocarcinoma.

Phase 2RecruitingEXACT Therapeutics ASNCT06850623Data as of May 2026

Treatment: Acoustic Cluster Therapy · Modified FOLFIRINOX — The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any anti-cancer treatment

Exception: palliative bypass procedure and bile duct stenting are allowed

Any prior anti-cancer treatment for pancreatic cancer (e.g. chemotherapy, surgery, radiation). Palliative bypass procedure and bile duct stenting are allowed.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

HonorHealth Research Institute · Scottsdale, Arizona
Stanford Cancer Center Palo Alto · Stanford, California
Beth Israel Deaconess Medical Center - Division of Hematology/Oncology · Boston, Massachusetts
Henry Ford Centre · Detroit, Michigan
Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital · Philadelphia, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify